TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01211795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical intraoral ketoprofen gel
Description: 20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
Study: NCT02318082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Study: NCT02731924

Intervention type: PROCEDURE
Intervention: Ultrasound for Appendicitis
Description: Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
Study: NCT03342742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Weight loss behavioral intervention via one of two strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Weight loss behavioral intervention via one of two strategies.
Study: NCT01640288

Intervention type: OTHER
Group type: OTHER
Intervention: High Resolution CT of the Chest
Description: High Resolution CT of the Chest, single visit

Intervention type: OTHER
Group type: OTHER
Intervention: High Resolution CT of the Chest
Description: High Resolution CT of the Chest, single visit
Study: NCT01909037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flexofytol (bio-optimized curcumin)
Description: 2x3 caps/day (before breakfast and in the evening) for 3 months
Study: NCT01077440

Intervention type: GENETIC
Intervention: DNA analysis
Description: DNA analysis will be performed on samples collected.
Study: NCT03987893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-3350 with Electolytes
Description: experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
Study: NCT01251380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Intramuscular (IM) injection on day 1 of each treatment cycle.
Study: NCT01077440

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: A polymerase chain reaction (PCR) assessment will be done on the samples collected.

Intervention type: OTHER
Intervention: flow cytometry
Description: Flow cytometry will be done on the samples collected.
Study: NCT03752307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoxsuprine Hydrochloride
Description: Compounded Isoxsuprine hydrochloride capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
Study: NCT00532285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Gemcitabine
Description: Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
Study: NCT04405076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.351
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.351
Description: Sterile liquid for injection
Study: NCT01077440

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory biomarker analysis will be performed on the samples collected.
Study: NCT02568059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sahastara remedy alcoholic extract
Description: comparison of different dose of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sahastara remedy alcoholic extract
Description: comparison of different dose of drug
Study: NCT04184349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LA group
Description: In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B Group
Description: In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
Study: NCT02772510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glove system with functional electrical stimulation
Description: Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
Study: NCT04683445

Intervention type: DRUG
Intervention: Eribulin
Description: Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle

Intervention type: DRUG
Intervention: Eribulin
Description: Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle

Intervention type: DRUG
Intervention: Eribulin
Description: Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle

Intervention type: DRUG
Intervention: pertuzumab
Description: Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle

Intervention type: DRUG
Intervention: Pyrotinib
Description: Pyrotinib，400mg，oral，every day

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Pembrolizumab，200mg，Intravenous infusion，3-week cycle

Intervention type: DRUG
Intervention: Camerlizumab
Description: Camerlizumab，200mg，Intravenous infusion，3-week cycle
Study: NCT02292706

Intervention type: DRUG
Intervention: Sofosbuvir
Description: Exposure of interest for participants who received sofosbuvir in a previous Gilead study for chronic HCV infection.

Intervention type: DRUG
Intervention: Ribavirin

Intervention type: DRUG
Intervention: Ribavirin

Intervention type: DRUG
Intervention: Ribavirin
Study: NCT02772510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional electrical stimulation
Description: Functional electrical stimulation on distal upper extremity
Study: NCT04579042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cartilaginous batten graft septoplasty
Description: septoplasty using cartilaginous batten graft in cases with caudal septal deviation
Study: NCT01485562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 tablets, administered sublingually if the woman experiences a PPH
Study: NCT02162290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval exercise training
Description: Exercise bouts in low and high intensities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Study: NCT00729339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mosapride for the first month and placebo for the 2nd month
Description: lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for the first and mosapride for the second month
Description: lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
Study: NCT00080743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gefitinib
Description: 250 mg po once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: 250 mg po once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg po once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill po once daily
Study: NCT02822989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve stimulation
Description: Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
Study: NCT03464006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Support Module
Description: The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The normal care that patients receive at the institution.
Study: NCT03880981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: ibuprofen 600mg Po q 6 hours prn pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 600mg po q6 hours prn pain
Study: NCT02567279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab subcutaneous injections
Description: Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous injections
Description: Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
Study: NCT04455165

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
Study: NCT01755091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Study: NCT01430013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar and CHOPT
Description: Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
Study: NCT01498952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573 (1 of 3 doses)
Description: MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573 (1 of 3 doses)
Description: MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573 (1 of 3 doses)
Description: MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573 (1 of 3 doses)
Description: MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
Study: NCT01755091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dronabinol)
Study: NCT01498952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
Study: NCT02280590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin(Cresnon®)
Description: 10mg
Study: NCT03636178

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Classic alar base suture technique
Description: An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modified alar base suture technique
Description: The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
Study: NCT00082277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg/Day Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg/Day Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg/Day Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate Sodium
Description: 35mg/week, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate Sodium
Description: 35mg/week, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate Sodium
Description: 35mg/week, oral
Study: NCT02375165

Intervention type: PROCEDURE
Intervention: phlebotomy
Description: phlebotomy for collection of plasma and serum, \~30 cc

Intervention type: PROCEDURE
Intervention: phlebotomy
Description: phlebotomy for collection of plasma and serum, \~30 cc
Study: NCT02595801

Intervention type: OTHER
Intervention: Surgery in early childhood
Description: Surgical interventions in early childhood (prior to completion of Early Development Instrument)
Study: NCT03532828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polysomnography
Description: Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polysomnography
Description: Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
Study: NCT00943748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deferiprone
Description: A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
Study: NCT03748446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon
Description: The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen gas
Description: nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
Study: NCT02791451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: To predict exacerbation of COPD with wireless telemonitoring
Study: NCT04522726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weiyang Yuping Fang
Description: Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weiyang Yuping Fang
Description: Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
Study: NCT02301195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic horseback riding
Description: Inclusion of horses as part of the therapeutic experience

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barn Activity Intervention
Description: Equine-focused educational activities in small group setting without horses
Study: NCT03051477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helixor® M
Description: 3-hour IV infusion on Monday, Wednesday, and Friday of each week.
Study: NCT01618565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands-On Training
Description: one-time, 30 minute hands-on training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demonstration
Description: 30 minutes passive training
Study: NCT00604682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC10004
Description: 2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
Study: NCT04428814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P43
Description: 45mg single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P43
Description: 45mg single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Stelara
Description: 45mg single dose
Study: NCT02280590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin(Crestor®)
Description: 10mg
Study: NCT00934739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, Celebrex
Description: Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
Study: NCT04428814

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Stelara
Description: 45mg single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Stelara
Description: 45mg single dose
Study: NCT03511599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine 100mg
Study: NCT02667262

Intervention type: OTHER
Intervention: Algorithm to identify patients experiencing opioid abuse/addiction
Study: NCT02675933

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
Study: NCT05523648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic Hepatitis B
Description: 92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Hepatitis B
Description: 92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
Study: NCT03646916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Gluco-corticosteroid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No dexamethasone
Description: Nothing
Study: NCT00864968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabumetone 750 mg tablets, single dose
Description: A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabumetone 750 mg tablets, single dose
Description: B: Active comparator Subjects received Teva formulated products under fasting conditions